Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Acrivon Therapeutics, Inc. (ACRV)
TipRanksApr 27 20:10
Jefferies Upgrades Vistagen Therapeutics to Buy, Raises Price Target to $15
BenzingaDec 7, 2023 18:35
Vistagen Therapeutics Analyst Ratings
BenzingaDec 7, 2023 18:33
Hearing Vistagen Therapeutics Upgraded From A Hold To A Buy At Jefferies; Price Target $15
BenzingaDec 7, 2023 08:10
Vistagen Therapeutics Analyst Ratings
BenzingaNov 15, 2023 01:46
VistaGen Therapeutics' Robust Financial Position and Promising Pipeline Underpin Buy Rating: A Comprehensive Analysis
TipRanksNov 11, 2023 23:15
Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Rhythm Pharmaceuticals (RYTM)
TipRanksOct 19, 2023 01:40
Maxim Cuts Price Target on VistaGen Therapeutics to $12 From $30, Maintains Buy Rating
MT NewswiresOct 18, 2023 01:43
Maxim Group Reaffirms Their Buy Rating on VistaGen Therapeutics (VTGN)
TipRanksSep 14, 2023 04:05
Analysts Offer Insights on Healthcare Companies: CymaBay Therapeutics (CBAY) and VistaGen Therapeutics (VTGN)
TipRanksSep 7, 2023 01:50
Maxim Group Maintains Buy on Vistagen Therapeutics, Maintains $30 Price Target
BenzingaSep 6, 2023 03:35
Vistagen Therapeutics Analyst Ratings
BenzingaSep 6, 2023 01:58
Maxim Group Remains a Buy on VistaGen Therapeutics (VTGN)
TipRanksAug 12, 2023 22:45
Maxim Group Upgrades Vistagen Therapeutics to Buy, Announces $30 Price Target
BenzingaAug 8, 2023 07:09
Vistagen Therapeutics Analyst Ratings
BenzingaAug 8, 2023 07:04
Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Humacyte (HUMA)
TipRanksMar 24, 2023 22:42
Maxim Group Sticks to Their Hold Rating for VistaGen Therapeutics (VTGN)
TipRanksFeb 9, 2023 23:16
Maxim Group Sticks to Its Hold Rating for VistaGen Therapeutics (VTGN)
TipRanksDec 8, 2022 02:05
Robert W. Baird Reaffirms Their Hold Rating on VistaGen Therapeutics (VTGN)
TipRanksNov 14, 2022 11:50
No Data
No Data